Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis

Journal of Viral Hepatitis

Volumn 6, Issue 5, 1999, Pages 357-365

  Hayashi, N ^a,b   Mita, E ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Cytotoxic T lymphocyte; Fas; Fas ligand; Hepatitis B virus; Hepatitis C virus

Indexed keywords

FAS LIGAND;

APOPTOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS; VIRUS PATHOGENESIS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER DISEASES; MEMBRANE GLYCOPROTEINS; MICE;

EID: 0032885603     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00175.x     Document Type: Review

References (76)

1. Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology 1995; 21: 1725-1741.
2. Galle PR. Apoptosis in liver disease. J Hepatol 1997; 27: 405-412.
3. Bursch W, Paffe S, Putz B, Barthel G, Schulte-Hermann R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis 1990; 11: 847-853.
4. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99: 1472-1477.
5. Kägi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
6. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
7. Depraetere V, Golstein P. Fas and other cell death signaling pathways. Semin Immunol 1997; 9: 93-107.
8. Watanabe-Fukunaga R, Brannan CI, Itoh N et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274-1279.
9. Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-3813.
10. Ni R, Tomita Y, Matsuda K et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994; 215: 332-337.
11. Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95(APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230.
12. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effects of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
13. Cheng J, Liu C, Yang P, Zhou T, Mountz JD. Increased lymphocyte apoptosis in Fas ligand transgenic mice. J Immunol 1997; 159: 674-684.
14. Muruve DA, Nicolson AG, Manfro RC, Strom TB, Sukhatme VP, Libermann TA. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Human Gene Ther 1997; 8: 955-963.
15. Zhang HG, Bilbao G, Zhou T et al. Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J Virol 1998; 72: 2483-2490.
16. + cytotoxic T-lymphocyte clone. J Virol 1994; 68: 7540-7545.
17. Ando K, Moriyama T, Guidotti LG et al. Mechanism of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-1554.
18. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med 1997; 3: 409-413.
19. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621-627.
20. Lacronique V, Mignon A, Fabre M et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Med 1996; 2: 80-86.
21. Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 1996; 184: 2067-2072.
22. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996; 184: 2067-2072.
23. Künstle G, Leist M, Uhlig S et al. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α. Immunol Lett 1997; 55: 5-10.
24. Mignon A, Guidotti JE, Mitchell C et al. Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes. Nature Med 1998; 4: 1185-1188.
25. Ando K, Hiroishi K, Kaneko T et al. Perform, Fas/Fas ligand, and TNFα pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158: 5283-5291.
26. Takehara T, Hayashi N, Mita E et al. Delayed Fas-mediated hepatocyte apoptosis during liver regeneration in mice: hepatoprotective role of TNFα. Hepatology 1998; 27: 1643-1651.
27. Kosai K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 1998; 244: 683-690.
28. Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-1359.
29. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-135.
30. Jin Y, Fuller L, Carreno M et al. The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage. J Clin Immunol 1997; 17: 140-153.
31. Ferenbach DA, Haydon GH, Rae F, Malcomson RD, Harrison DJ. Alteration in mRNA levels of Fas splice variants in hepatitis C-infected liver. J Pathol 1997; 183: 299-304.
32. Mochizuki K, Hayashi N, Hiramatsu N et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996; 24: 1-7.
33. Luo KX, Zhu YF, Zhang LX, He HT, Wang XS, Zhang L. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J Viral Hep 1997; 4: 303-307.
34. Ito Y, Hayashi N, Sasaki Y et al. Little expression of protooncogene bcl-2 in tumourous cells of hepatocellular carcinoma with chronic hepatitis C virus infection. Int Hepatol Commun 1996; 4: 316-325.
35. Zhao M, Zhang NX, Economou M, Blaha I, Laissue JA, Zimmermann A. Immunohistochemical detection of bcl-2 protein in liver lesions: bcl-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia. Histopathology 1994; 25: 237-245.
36. Okazaki M, Hino K, Fujii K, KobayashiN, Okita K. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996: 41: 2453-2458.
37. 51Cr-labeled human hepatocytes as target cells for cytotoxicity mediated by freshly isolated liver-infiltrating lymphocytes. J Immunol Methods 1993; 164: 69-77.
38. Mita E, Hayashi N, Iio S et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468-474.
39. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
40. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1(CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622-4630.
41. Krams SM, Fox CK, Beatty PR et al. Human hepatocytes produce an isoform of FAS that inhibits apoptosis. Transplantation 1998; 65: 713-721.
42. Iio S, Hayashi N, Mita E et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998; 29: 517-523.
43. Seishima M, Takemura M, Saito K, Ando K, Noma A. Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol 1997; 27: 424-425.
44. Jodo S, Kobayashi S, Nakajima Y et al. Elevated serum levels of soluble Fas/APO-1(CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998; 112: 166-171.
45. Kayagaki N, Kawasaki A, EbataT et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777-1783.
46. Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nature Med 1996; 2: 317-322.
47. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1997; 4: 31-36.
48. Sato K, Kimura F, Nakamura Y et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 1996; 94: 379-382.
49. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527-1531.
50. Natoli G, Ianni A, Costanzo A et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157-1164.
51. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229: 68-76.
52. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996; 226: 176-182.
53. Owen-Schaub LB, Zhang W, Cusack JC et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
54. Chirillo P, Pagano S, Natoli G et al. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc Natl Acad Sci USA 1997; 94: 8162-8167.
55. Takada S, Kaneniwa N, Tsuchida N, Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 1997; 15: 1895-1901.
56. Schaefer S, Seifer M, Grimmsmann T et al. Properties of tumour suppressor p53 in murine hepatocyte lines transformed by hepatitis B virus X protein. J Gen Virol 1998; 79: 767-777.
57. Yano H, Fukuda K, Haramaki M et al. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines. J Hepatol 1996; 25: 454-464.
58. Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 1996; 149: 429-437.
59. Ito Y, Takeda T, Umeshita K et al. Fas antigen expression in hepatocellular carcinoma tissues. Oncol Rep 1998; 5: 41-44.
60. Sansonno D, Cornacchiulo V, Racanelli V, Dammacco F. In situ simultaneous detection of hepatitis C virus RNA and hepatitis C virus-related antigens in hepatocellular carcinoma. Cancer 1997; 80: 22-33.
61. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990; 7: 243-260.
62. Takada S, Koike K. Trans-activation function of a 3′ truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc Natl Acad Sci USA 1990; 87: 5628-5632.
63. Müller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95(APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413.
64. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
65. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521-4524.
66. Rensing-Ehl A, Frei K, Flury R et al. Local Fas/APO-1(CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995; 25: 2253-2258.
67. Taïeb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 1998; 351: 1930-1931.
68. Okazaki M, Hino K, Fujii K et al. Immunohistochemical study of Fas antigen in liver of patients with chronic hepatitis and autoimmune liver disease. Int Hepatol Commun 1995; 3: 285-289.
69. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1998; 26: 1399-1405.
70. Strand S, Hofmann WJ, Grambihler A et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95(APO-1/Fas) mediated apoptosis. Nature Med 1998; 4: 588-593.
71. Krams SM, Martinez OM. Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis 1998; 18: 153-167.
72. Yokoyama I, Hayakawa A, Hayashi S, Kobayashi T, Negita M, Takagi H. Fas antigen expression of hepatocytes and its modification by immunosuppressants. Dig Dis Sci 1997; 42: 2471-2475.
73. Benedetti A, Jezequel AM, Orlandi F. Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver. J Hepatol 1988; 7: 319-324.
74. Adachi M, Suematsu S, Kondo T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet 1995; 11: 294-300.
75. Le-Deist F, Emile JF, Rieux-Laucat F et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996; 348: 719-723.
76. Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.